Our Services
Medical Information
Helpful Resources
Published on: 9/23/2026
Abrysvo (RSVpreF) is currently the only RSV vaccine approved for use during pregnancy, and it is considered safe when given as a single dose between 32 and 36 weeks of gestation, usually during RSV season, to pass protective antibodies to the baby. Reported side effects are typically mild and short lived, such as injection site pain, headache, muscle aches, and nausea, though clinical trials noted a small imbalance in preterm births that shaped the recommended timing window. Other RSV vaccines, including Arexvy and mResvia, are not authorized for pregnant patients, and timing, gestational age, and whether your baby may instead receive nirsevimab are all important factors to weigh, so see below to understand more before deciding.
If you are pregnant and weighing RSV protection, unusual symptoms like fever, contractions, reduced fetal movement, or a worsening cough deserve prompt attention rather than guesswork, since they can point to issues unrelated to vaccination. A free, instant, online symptom check can help you organize what you are feeling, understand possible causes, and see how urgent it may be. Taking a few minutes now can make your next conversation with your OB or midwife clearer and faster, so you leave with answers instead of more questions.
Last reviewed for medical accuracy: 09/23/2025
Is the RSV Vaccine Safe During Pregnancy?
Respiratory Syncytial Virus (RSV) can cause severe lung and breathing problems in newborns and infants. In 2023, health authorities approved an RSV vaccine specifically for pregnant people to help protect babies during their first vulnerable months. Below, you’ll find clear, up-to-date information on RSV vaccine pregnancy safety, benefits, side effects, and practical steps you can take.
RSV is a common virus that usually causes mild, cold-like symptoms in older children and adults. In babies under 6 months, however, RSV can lead to:
Vaccinating pregnant people helps antibodies pass through the placenta, giving newborns early protection during peak RSV season (fall through spring).
Large studies enrolled over 7,000 pregnant participants across multiple countries. Key findings include:
These safety outcomes align with decades of data on other maternal vaccines (e.g., pertussis, flu).
You may experience mild side effects, which are generally short-lived and manageable at home:
Most people feel back to normal within 48 hours. If discomfort persists beyond 3 days or symptoms worsen, contact your healthcare provider.
“I’m worried about long-term effects on my baby.”
Decades of maternal vaccine research (including flu and Tdap) show no long-term risks. With RSVpreF, follow-up data confirm healthy infant growth and development through at least six months.
“Could the vaccine trigger preterm labor?”
Clinical trials found no increase in preterm birth rates compared to unvaccinated groups.
“I already got my flu shot—can I get both?”
Yes. You can safely receive the RSV vaccine alongside other recommended vaccines during the third trimester. Staggering appointments by a few days can reduce overlap of side effects if you prefer.
The RSV vaccine is recommended for:
Your provider can help you decide whether vaccination timing fits your individual prenatal schedule.
If you’re ever unsure about symptoms you or your baby are experiencing, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Every medical decision involves weighing potential benefits against possible side effects. In this case:
Overall, leading obstetric and pediatric experts agree that maternal RSV vaccination provides more benefits than risks.
If you experience any severe or life-threatening symptoms—either related to vaccination or otherwise—please speak to a doctor right away. Your healthcare team is the best resource for urgent concerns.
For quick reassurance about everyday symptoms, try a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Stay informed, stay protected, and speak to your doctor about any questions or serious health issues.
(References)
* Mazur NI, Terstappen J, Baral R, Bardají A, Beutels P, Buchholz UJ, Cohen C, Crowe JE Jr, Cutland CL, Eckert L, Feikin D, Fitzpatrick T, Fong Y, Graham BS, Heikkinen T, Higgins D, Hirve S, Klugman KP, Kragten-Tabatabaie L, Lemey P, Libster R, Löwensteyn Y, Mejias A, Munoz FM, Munywoki PK, Mwananyanda L, Nair H, Nunes MC, Ramilo O, Richmond P, Ruckwardt TJ, Sande C, Srikantiah P, Thacker N, Waldstein KA, Weinberger D, Wildenbeest J, Wiseman D, Zar HJ, Zambon M, Bont L. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis. 2023 Jan;23(1):e2-e21. doi: 10.1016/S1473-3099(22)00291-2. Epub 2022 Aug 8. PMID: 35952703; PMCID: PMC9896921.
* Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, Baker J, Pérez Marc G, Radley D, Shittu E, Glanternik J, Snaggs H, Baber J, Zachariah P, Barnabas SL, Fausett M, Adam T, Perreras N, Van Houten MA, Kantele A, Huang LM, Bont LJ, Otsuki T, Vargas SL, Gullam J, Tapiero B, Stein RT, Polack FP, Zar HJ, Staerke NB, Duron Padilla M, Richmond PC, Koury K, Schneider K, Kalinina EV, Cooper D, Jansen KU, Anderson AS, Swanson KA, Gruber WC, Gurtman A, MATISSE Study Group. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023 Apr 20;388(16):1451-1464. doi: 10.1056/NEJMoa2216480. Epub 2023 Apr 5. PMID: 37018474.
* Soni A, Kabra SK, Lodha R. Respiratory Syncytial Virus Infection: An Update. Indian J Pediatr. 2023 Dec;90(12):1245-1253. doi: 10.1007/s12098-023-04613-w. Epub 2023 Jun 16. PMID: 37326948.
* Agac A, Kolbe SM, Ludlow M, Osterhaus ADME, Meineke R, Rimmelzwaan GF. Host Responses to Respiratory Syncytial Virus Infection. Viruses. 2023 Sep 26;15(10). doi: 10.3390/v15101999. Epub 2023 Sep 26. PMID: 37896776; PMCID: PMC10611157.
* Phijffer EW, de Bruin O, Ahmadizar F, Bont LJ, Van der Maas NA, Sturkenboom MC, Wildenbeest JG, Bloemenkamp KW. Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes. Cochrane Database Syst Rev. 2024 May 2;5(5):CD015134. doi: 10.1002/14651858.CD015134.pub2. Epub 2024 May 2. PMID: 38695784; PMCID: PMC11064886.
* Roman F, Burny W, Ceregido MA, Laupèze B, Temmerman ST, Warter L, Coccia M. Adjuvant system AS01: from mode of action to effective vaccines. Expert Rev Vaccines. 2024 Jan-Dec;23(1):715-729. doi: 10.1080/14760584.2024.2382725. Epub 2024 Aug 5. PMID: 39042099.
* Terstappen J, Hak SF, Bhan A, Bogaert D, Bont LJ, Buchholz UJ, Clark AD, Cohen C, Dagan R, Feikin DR, Graham BS, Gupta A, Haldar P, Jalang'o R, Karron RA, Kragten L, Li Y, Löwensteyn YN, Munywoki PK, Njogu R, Osterhaus A, Pollard AJ, Nazario LR, Sande C, Satav AR, Srikantiah P, Stein RT, Thacker N, Thomas R, Bayona MT, Mazur NI. The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access. Lancet Infect Dis. 2024 Dec;24(12):e747-e761. doi: 10.1016/S1473-3099(24)00455-9. Epub 2024 Sep 23. PMID: 39326422; PMCID: PMC12311909.
* Simões EAF, Pahud BA, Madhi SA, Kampmann B, Shittu E, Radley D, Llapur C, Baker J, Pérez Marc G, Barnabas SL, Fausett M, Adam T, Perreras N, Van Houten MA, Kantele A, Huang LM, Bont LJ, Otsuki T, Vargas SL, Gullam J, Tapiero B, Stein RT, Polack FP, Zar HJ, Staerke NB, Padilla MD, Richmond PC, Sarwar UN, Baber J, Koury K, Lino MM, Kalinina EV, Li W, Cooper D, Anderson AS, Swanson KA, Gurtman A, Munjal I, MATISSE (Maternal Immunization Study for Safety and Efficacy) Clinical Trial Group. Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial. Obstet Gynecol. 2025 Feb 1;145(2):157-167. doi: 10.1097/AOG.0000000000005816. Epub 2025 Jan 2. PMID: 39746212; PMCID: PMC11731064.
* Scott J, Abers MS, Marwah HK, McCann NC, Meyerowitz EA, Richterman A, Fleming DF, Holmes EJ, Moat LE, Redepenning SG, Smith EA, Stoddart CJ, Sundaram ME, Ulrich AK, Alba C, Anderson CJ, Arpey MK, Borre E, Ladines-Lim J, Mehr AJ, Rich K, Watts C, Basta NE, Jarolimova J, Walensky RP, Dugdale CM. Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026. N Engl J Med. 2025 Dec 4;393(22):2221-2242. doi: 10.1056/NEJMsa2514268. Epub 2025 Oct 29. PMID: 41160817.
* Jabagi MJ, Bertrand M, Gabet A, Kolla E, Olié V, Zureik M. Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus-Related Hospitalization in Newborns. JAMA. 2026 Mar 3;335(9):787-798. doi: 10.1001/jama.2025.24082. PMID: 41428474; PMCID: PMC12723599.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.